Scientists test two ogbonge weight loss drugs to see which one be di best
Wia dis foto come from, Getty Images
- Author, James Gallagher
- Role, Health and science correspondent
- Read am in 3 mins
Di first head-to-head trial of two ogbonge weight-loss drugs show say Mounjaro dey more effective pass im rival Wegovy.
Both drugs bin lead to substantial weight loss, but Mounjaro 20% weight reduction, afta 72 weeks of treatment, pass di 14% from Wegovy, according to di trial findings.
Researchers wey bin lead di trial say both drugs get a role, but Mounjaro fit help those wey get more weight to lose.
Both drugs trick di brain to make dem feel full so dem go eat less and instead burn fat wey dey stored for di body - but small difference dey on how dem work wey explain di difference on how effective dem be.
Wegovy, also dey known as semaglutide, e dey copy one hormone wey di body dey release afta food to off one appetite switch for di brain. Mounjaro, or tirzepatide, dey off two.
Di trial, wey bin dey paid for by Eli Lilly, di manufacturer of Mounjaro, involve 750 obese pipo, wit an average weight of 113kg (nearly 18 stone).
Dem ask dem to take di highest dose dia body fit tolerate of one of di two drugs.
Di findings, wey dem present for di European Congress on Obesity for Malaga and for di New England Journal of Medicine, show say:
- 32% of di pipo lose a quarter of dia body weight wit Mounjaro compared to 16% on Wegovy.
- Those on Mounjaro bin lose an average of 18cm from dia waistlines compared wit 13cm on Wegovy.
- Those on Mounjaro get a better blood pressure, a better blood sugar and a better cholesterol levels.
- Both of dem get similar levels of side-effects.
- Women tend to lose more weight dan men.
Dr Louis Aronne, wey conduct di trial for di Comprehensive Weight Control Center for Weill Cornell Medicine for New York, say: "Di majority of pipo wit obesity go do well wit semaglutide (Wegovy), those wey dey di higher end fit ultimately do better wit tirzepatide (Mounjaro)."
Private tirzepatide sales dey 'well ahead of semaglutide'
Wia dis foto come from, Getty Images
For UK, di two medicines dey available from specialist weight-management services, but you fit buy am privately.
Prof Naveed Sattar, from di University of Glasgow, say di drugs na "good options" for patients, but while "many go dey satisfied wit 15% weight loss… many want as much weight loss as possible".
"For UK, tirzepatide sales privately now dey well ahead of semaglutide – dat na just di reality - and dis paper go increase am wey I imagine," im add.
However, Wegovy also dey licensed for oda conditions – like preventing heart attacks – while di equivalent trials with Mounjaro dem neva complete am.
Plenty research on weight-loss drugs still dey go on. Dem dey do test on top higher doses of di current drugs, also dem dey investigate new ways to take dem like oral pills and different ways new medicine go act for di body.
E mean say no body know who di final winner go be be for now.
Prof Sattar say di amount of research wey dey take place mean say we fit dey near di point wia "obesity prevention fit also dey possible soon", but advise say "e go dey by far better" to make our society healthier to prevent more pipo from developing obesity.
